Sanofi sues Eli Lilly over challenge to top diabetes drug Lantus (Reuters). Reference links: Sanofi files suit in the US to defend its patent rights (Sanofi press release, PDF).

Sanofi has announced that its top-selling insulin treatment, Lantus, proved three times more likely than standard care to maintain targeted blood sugar levels in patients with pre-diabetes or ...

The French firm announced a $35 (£28) per month price cap on Lantus for those with private insurance. Sanofi's changes follow in the footsteps of other drugmakers, Eli Lilly and Novo Nordisk.

The 25 drugs included in Sanofi’s credit model include some of its top-sellers, like Dupixent, which has brought in $9.6 billion in global sales year to date, and Lantus, which has made almost ...

GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus, an insulin glargine injection and Sanofi's most widely ...